Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.

Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.

Recently a number of randomized trials have shown that patients with advanced colorectal cancer do not benefit from therapies targeting the epidermal growth factor receptor when their tumors harbor mutations in the KRAS, BRAF and PIK3CA genes. We developed two multiplex assays that simultaneously sc...

Full description

Bibliographic Details
Main Authors: Irene Lurkin, Robert Stoehr, Carolyn D Hurst, Angela A G van Tilborg, Margaret A Knowles, Arndt Hartmann, Ellen C Zwarthoff
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2809099?pdf=render

Internet

http://europepmc.org/articles/PMC2809099?pdf=render

Similar Items